REPLY EXHIBIT 5


Reply Exhibit 5 – Theriva Biologics web page therivabio.com/our-pipeline/ as it appeared on November 7, 2026

Nejmeh v. Theriva Biologics, Inc., No. 3:26-cv-00705-ART-CSD (D. Nev.)

Source: therivabio.com/our-pipeline/, printed November 7, 2026.

Theriva™ BIOLOGICS

OUR PIPELINE



OVERVIEW

SYN-004

Prevention of aGVHD in allo-HCT

Pre-IND	Phase 1	Phase 2	Phase 3

Phase 1b/2a study On-going

---

*Based on Management's current beliefs and expectations. aGVHD acute graft-vs-host disease; allo-HCT allogeneic hematopoietic cell transplant. Gem/nab-P gemcitabine/nab-paclitaxel. HNSCC head and neck squamous cell carcinoma. IV intravenous. IVit intravitreal. PDAC pancreatic ductal adenocarcinoma

Aligned with our oncology focus, our oral β-lactamase product SYN-004 (ribaxamase) continues to be evaluated for the prevention of critical adverse outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT) to treat hematologic cancers. 80% to 90% of these patients will be treated with an intravenous β-lactam antibiotic that has been strongly associated with increased incidence and severity of acute graft-vs-host disease (aGVHD), vancomycin-resistant Enterococci (VRE) infection, and Clostridioides difficile infection (CDI). The prevention of one or all of these outcomes by SYN-004 coadministration may significantly improve treatment outcomes and reduce patient mortality.

Clinical Trial Overview

VIRAGE: VCN-01 (INTRAVENOUS) + GEMCITABINE / NAB-PACLITAXEL FOR PATIENTS WITH PDAC